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Background: Weight gain and obesity are common after kidney transplantation, particularly during the first year.
Obesity is a risk factor for the development of new-onset diabetes after transplantation, and is associated with
reduced graft survival. There is a lack of evidence for effective interventions to prevent weight gain after kidney
transplantation.
Methods/Design: The effect of INTEnsive Nutrition interventions on weight gain after kidney Transplantation
(INTENT) trial is a single-blind (outcomes assessor), randomised controlled trial to assess the effect of intensive
nutrition interventions, including exercise advice, on weight gain and metabolic parameters in the first year after
transplantation. Participants will be randomised during the first post-transplant month to either standard care
(four visits with a renal dietitian over twelve months) or intensive nutrition intervention (eight visits with a renal
dietitian over the first six months, four visits over the second six months, and three visits over the first six months with
an exercise physiologist). In the intensive intervention group, nutrition counselling will be provided using motivational
interviewing techniques to encourage quality engagement. Collaborative goal setting will be used to develop
personalised nutrition care plans. Individualised advice regarding physical activity will be provided by an exercise
physiologist. The primary outcome of the study is weight at six months after transplant, adjusted for baseline
(one month post-transplant) weight, obesity and gender. Secondary outcomes will include changes in weight
and other anthropometric measures over 12 months, body composition (in vivo neutron activation analysis, total
body potassium, dual-energy X-ray absorptiometry, and bioelectrical impedance), biochemistry (fasting glucose,
lipids, haemoglobin A1c and insulin), dietary intake and nutritional status, quality of life, and physical function.
Discussion: There are currently few randomised clinical trials of nutrition interventions after kidney
transplantation. The INTENT trial will thus provide important data on the effect of intensive nutrition interventions
on weight gain after transplant and the associated metabolic consequences. Additionally, by assessing changes in
glucose metabolism, the study will also provide data on the feasibility of undertaking larger multi-centre trials of
nutrition interventions to reduce the incidence or severity of diabetes after transplantation.
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Kidney transplantation represents the optimal form of
renal replacement therapy and, compared with dialysis
treatment, is associated with significantly improved sur-
vival [1,2], quality of life [3] and reduced costs over time
[4,5]. However, despite improvements in both patient
and graft survival, kidney transplant recipients continue
to have increased mortality compared with the general
population [6]. This is predominantly due to an increased
risk of cardiovascular disease [7,8]. Excessive weight gain,
obesity and diabetes are important risk factors for cardio-
vascular disease in transplant recipients, and are associ-
ated in multiple studies with an increased risk of death,
cardiac events and graft loss (necessitating a return to dia-
lysis treatment), even when confounding factors are taken
into account [9-13].
In the first year following kidney transplantation, there
is a significant incidence of excess weight gain and obesity
in transplant recipients, with average post-transplant
weight gains of 10-35% reported [14-18]. These changes
are associated with increased total body fat, reduced lean
muscle mass and reduced bone mineral density [17,19-22].
Excess weight gain in the first year after transplant has also
been shown to be a risk factor for the development of
metabolic syndrome and new-onset diabetes after trans-
plant (NODAT) [23-27]. Possible causes for weight gain
include the use of immunosuppressive medications
(such as corticosteroids), the relaxation of dietary re-
strictions associated with dialysis treatment (increased
freedom of food and fluid choices, which may lead to
increased energy intake), and improvements in well-
being and appetite associated with the resolution of the
uraemic state [10,28-30]. In addition, studies indicate
that many transplant recipients do not engage in ad-
equate levels of physical exercise and activity, despite
the improvements in overall well-being [31-33].
Despite concern about weight gain and obesity following
kidney transplantation, not all post-transplant weight gain
is considered undesirable. A high incidence of malnutri-
tion has been reported in patients receiving dialysis ther-
apies [34], even in those with a body mass index (BMI) in
the overweight or obese range [35]. Low BMI, malnutri-
tion and low muscle mass have been associated with poor
survival after kidney transplantation [36,37]. It is therefore
important to consider not only weight but other markers
of nutrition (including evidence for protein-energy wasting
and serum albumin) and body composition in the assess-
ment and treatment of kidney transplant recipients.
Importantly, weight gain in the first post-transplant year
has been shown to be associated with reduced graft sur-
vival [38], and obese individuals have an increased risk of
death and graft failure in the first 12 months compared
with individuals of normal weight [39]. Weight gain after
transplant therefore represents a potentially modifiablerisk factor for poor outcomes after transplantation that
might be an appropriate target for therapeutic intervention.
There are currently no evidence-based clinical guidelines
on specific interventions to prevent or manage excessive
weight gain and obesity after transplantation, due to a lack
of high quality evidence from randomised controlled trials.
On the basis of several non-randomised studies, the
Caring for Australasians with Renal Impairment (CARI)
guidelines have suggested that kidney transplant recipi-
ents be referred to a dietitian for advice to prevent weight
gain post-transplant, and that this advice should be re-
inforced via follow-up assessments on a regular basis
[40,41]. Guidelines from the Kidney Disease: Improving
Global Outcomes (KDIGO) initiative and the United
Kingdom (UK) Renal Association have suggested that
obesity is assessed at each visit and weight management
services should be available for patients [42,43].
In the general population, systematic reviews of rando-
mised studies have shown that interventions addressing
nutrition, behaviour and physical activity can be effective
in reducing weight in obese patients, although the effects
are often not sustained over the long term following the
intervention programme [44-46]. Interventions that in-
volve regular review (such as fortnightly during the first
three months and continued monitoring for at least
12 months) have shown the greatest benefits [47,48].
In kidney transplant patients, the few studies that have
considered the effects of nutrition and exercise interven-
tions on bodyweight within the 12 months after transplant
have had inconsistent results: significantly less weight gain
[49], a significant reduction in weight gain from baseline
for males [50], or no effect on bodyweight [51]. However,
the interpretation of results is limited by the study designs;
two studies were non-randomised [49,50] and one was de-
signed to assess the effects of the intervention on hyperlip-
idaemia [51].
Overall, there is a need to develop effective interventions
to minimise the detrimental effects of weight gain and
obesity on long-term kidney transplant outcomes. Rando-
mised controlled trials are needed to assess whether nutri-
tion interventions are likely to be effective in preventing
weight gain after kidney transplantation.
The effect of INTEnsive Nutrition interventions on
weight gain after kidney Transplantation (INTENT) trial
is a randomised controlled trial designed to evaluate the
effect of an intensive nutrition intervention, including
tailored advice regarding exercise and physical activity,
on weight gain in the first year following kidney trans-
plantation. In addition, detailed measures of the effects
of the nutrition intervention on other anthropometric
measures, body composition, glucose metabolism and
biochemical markers of metabolic risk, functional cap-
acity and quality of life will be performed. The trial will
also provide data on the feasibility of conducting larger
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or severity of diabetes after kidney transplantation.
Methods/Design
Study aims and hypothesis
The primary aim of the INTENT trial is to determine
whether the use of an intensive nutrition intervention, in-
cluding physical activity advice, following kidney trans-
plantation will be effective at reducing weight gain in the
first year post-transplant.
Secondary aims are to determine whether the use of an
intensive nutrition intervention will be associated with im-
provements in anthropometry, body composition, glucose
metabolism and markers of metabolic risk; also, whether
the use of an intensive nutrition intervention has any ef-
fects on dietary intake, nutritional status, quality of life,
and physical function.
Our hypothesis is that early intensive nutrition interven-
tion, including advice regarding physical activity, after kid-
ney transplantation will be effective at reducing weight
gain in the first post-transplant year, compared with stand-
ard post-transplant care.
The INTENT trial will be used to assess the feasibility
of undertaking a larger study to determine if nutrition in-
terventions early after kidney transplant can reduce the in-
cidence and severity of diabetes after transplantation (and
thus potentially the risk of cardiovascular events). The pri-
mary feasibility outcome will be whether a difference in
haemoglobin A1c (HbA1c) is observed between the inter-
vention and standard care groups at 12 months.
Study design
The INTENT trial is a single-centre, single-blind, rando-
mised controlled trial with outcomes assessment blinded toFigure 1 Flowchart of the INTENT trial.group allocations. An outline of the study is shown in
Figure 1.
Ethical considerations
Ethical approval has been obtained through the Northern
B Health and Disability Ethics Committee of the Ministry
of Health in New Zealand.
Target population and eligibility criteria
The target population for the trial will be adult kidney
transplant recipients, residing within the Auckland re-
gional area, and recruited during routine post-transplant
care within one month of a kidney transplant procedure
at Auckland City Hospital.
Inclusion criteria will include the following: age > 18 years;
stable graft function, as determined by the patient’s treating
physician; willing and able to participate in all trial proce-
dures for the duration of trial follow-up; and ability to pro-
vide written informed consent.
Exclusion criteria will include the following: severe obes-
ity, defined by BMI >40 kg/m2; underweight, defined by
BMI <18.5 kg/m2; evidence of significant malnutrition re-
quiring enteral or parenteral nutrition therapy; ongoing
significant medical complications that in the opinion of
the patient’s treating physician preclude involvement in
the trial; and considered likely to become pregnant during
the duration of the trial.
Diabetes, cardiovascular disease or other stable medical
co-morbidities post-transplant will not be exclusions per
se unless deemed to represent a contraindication to par-
ticipating in the trial by the patient’s treating physician. Pa-
tients who have been or are receiving treatment for acute
rejection will not be excluded, providing graft function is
stable at the time of entry to the trial in the opinion of the
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ical trial will not be an exclusion providing that such par-
ticipation will not compromise involvement in this trial, in
the opinion of the principal investigator.
Recruitment, randomisation and blinding
Potential participants will be identified during their
initial inpatient stay following transplantation at
Auckland City Hospital, or through the renal transplant
outpatient clinic following discharge. Eligible transplant
recipients will be invited to participate, given detailed in-
formation about the trial and, if agreeable, will be asked to
provide written informed consent. In order to participate,
transplant recipients will need to provide informed con-
sent and be randomised prior to one month post kidney
transplantation.
Participants will be randomised in a 1:1 ratio to receive
either intensive nutrition intervention or standard of care.
Randomisation will be performed externally by a statistical
consultant using a computer-generated sequence allocation
with permuted blocks of variable size, and stratified by
gender. Allocation concealment will be via sealed opaque
envelopes.
Formal study assessments of weight, anthropometry,
measures of body composition, and physical function will
be performed by one of the investigators, who will be
blinded to the group allocation of participants. Laboratory
staff blinded to the group allocations will perform all la-
boratory testing.
Nature of nutrition care
Nutrition care will follow the Nutrition Care Process
developed by the Academy of Nutrition and Dietetics,
Chicago USA. This involves assessment, diagnosis of
nutrition problem, intervention, monitoring and evalu-
ation [52]. Australian and New Zealand evidence-based
guidelines for the nutritional management of kidney
transplant recipients will be used [53,54].
Standard care group
Participants randomised to the standard care group will
receive standard post-transplant care as per usual local
practice. This includes immunosuppressive medications
to prevent rejection and other treatments under the dir-
ection of the treating physician and renal transplant team.
Standard immunosuppression includes a calcineurin in-
hibitor (cyclosporine or tacrolimus as determined by the
treating physician), mycophenolate, steroids, and basilixi-
mab as induction therapy.
Current standard nutrition care after kidney transplant-
ation at Auckland City Hospital includes assessment by a
renal dietitian during the inpatient stay. Patients are given
resources guiding them on healthy eating and food safety
after transplant, and nutrition interventions to address anyidentified nutritional problems. Standard outpatient nutri-
tion care involves an individual consultation with a spe-
cialist renal dietitian at 1, 3 and 12 months post-transplant
alongside regular physician appointments.Intensive nutrition intervention group
Patients randomised to the intensive nutrition inter-
vention group will, in addition to standard care, re-
ceive more frequent counselling with a specialist renal
dietitian throughout the trial. These will commence at
one month post-transplant and include an additional 8
visits overall compared to the standard care group (see
Table 1). Participants will also receive individualised
assessment and advice regarding physical activity and
exercise, via formal consultations with an exercise physiolo-
gist at 2 months, 3 months and 6 months post-transplant.
Individualised nutrition counselling will be provided
using motivational interviewing techniques to encourage
quality engagement. Personal nutrition plans will be de-
veloped using S.M.A.R.T. action steps, i.e. specific, mea-
sureable, achievable, relevant and time-limited [55].
Prior to full reviews at 1, 3, 6 and 12 months, a self-
administered 3-day food diary record will be completed
by participants and analysed using appropriate analysis
software (e.g. FoodWorks® Professional [Xyris software]).
Dietary intake data will be compared to evidence-based
recommendations on nutrient requirements after renal
transplant and used to guide nutrition prescriptions. At
follow-up reviews, renal dietitians will assess progress,
goal setting and adherence to dietary recommendations.
Adherence will be measured using rulers to assess motiv-
ation to change, level of achievement of patient-centred
goals and review of action steps taken in patient action
plans.Primary and secondary outcomes
The primary outcome will be body weight at 6 months
post-transplant, adjusted for weight at baseline (one month
post-transplant), pre-existing obesity (BMI ≥30 kg/m2), and
gender.
Secondary outcomes will include the following: change
in weight and other anthropometric measures at 3, 6
and 12 months post-transplant; change in gold-standard
body composition parameters post-transplant; validity of
bio-electrical impedance assessment as compared with gold-
standard body composition analysis in kidney transplant
recipients; change in biochemical measures post-transplant
(e.g. lipid profile and markers of insulin resistance); adher-
ence to dietary advice in the intervention group; level of
physical activity and physical functional capacity in trans-
plant recipients; and quality of life in transplant recipients.
In addition, a cost-effectiveness analysis of intensive nutri-
tion intervention will be undertaken taking into account the
Table 1 Schedule of nutrition assessment, education and advice provided by renal dietitian and exercise physiologist
(intensive nutrition intervention group)
Months 1-3 Fortnightly review with dietitian to undertake initial assessments, determine progress, goals and adherence to recommendations
Full review of dietary intake and adequacy of adherence to recommendations to be undertaken at 1 month and 3 months
(including 3-day food diary and analysis)
Exercise advice (including a consultation with an exercise physiologist at 8 and 12 weeks to provide tailored advice)
regarding physical activity and a review of physical activity adherence
Months 4-6 Monthly review with dietitian to assess progress, goals and adherence to recommendations, and give further education
and advice as appropriate
Full review of dietary intake and adequacy of adherence to recommendations to be undertaken at 6 months (including
3-day food diary and analysis)
Exercise advice (including a consultation with an exercise physiologist at 6 months to provide tailored advice) regarding
physical activity and a review of physical activity adherence
Months 7-12 Bi-monthly review with dietitian to assess progress, goals and adherence to recommendations, and give further education
and advice as appropriate
A final review of diet history and adequacy of adherence to recommendations to be undertaken at 12 months (including
3-day food diary and analysis)
Exercise advice to promote adequate physical activity and review of physical activity adherence
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changes in weight and quality of life.
In order to determine the feasibility of undertaking
larger multi-centre trials of nutrition interventions to
reduce the incidence or severity of diabetes after trans-
plantation, the difference in HbA1c observed between
the intervention and standard care groups at 12 months
will be reported as an exploratory feasibility outcome.
Data collection
Standard demographic, clinical and laboratory data (in-
cluding medication details) will be collected at baseline
(1 month) and at 3, 6 and 12 months post-transplant.
This will include details of any acute medical issues, clin-
ical or other adverse events, graft function, acute rejection,
hospital admissions, development of diabetes, or any other
issues that might affect nutritional status or change in
weight. Formal study assessments (blinded to group allo-
cation) will be undertaken at baseline (1 month), and at 3,
6 and 12 months (Table 2).
Anthropometry and body composition
Standardised anthropometric measurements will include
body weight, BMI, waist circumference and waist-hip
ratio, mid-arm circumference and skin-fold thickness.
These will be performed using calibrated instruments
stored permanently in the Body Composition Laboratory
at the University of Auckland. To ensure standardisation,
the same equipment will be used for all measurements in
all patients.
Body composition measurements will include gold-
standard methods: dual-energy x-ray absorptiometry
(DEXA) to determine fat mass [56,57], total body po-
tassium to assess body cell mass [58], in vivo neutron
activation analysis for body nitrogen to determine totalbody protein [59], and deuterium dilution to determine
total body water [60]. In addition, bioelectrical imped-
ance assessment will be carried out as a surrogate
measurement of total body water, extracellular water
and fat mass [61].
Nutritional status, physical activity and quality of life
Nutritional status will be assessed using the patient-
generated subjective global assessment (PG-SGA) [62,63].
Physical activity will be assessed using the New Zealand
Physical Activity Questionnaire – short form (NZPAQ-SF),
a modified version of the International Physical Activity
Questionnaire (IPAQ) [64,65]. The Short Form 36 (SF-36)
will be used to assess quality of life [66].
Physical function
The following physical function assessments will be car-
ried out: gait speed, hand grip strength, and sit-to-stand-
to-sit test (to assess lower extremity strength) [67-69].
Biochemistry
During the formal study assessments at baseline
(1 month), 3, 6 and 12 months, specific biochemical
markers of glucose metabolism and metabolic risk
will be measured. Blood samples will be collected
after an overnight fast and assayed for glucose, insu-
lin, HbA1c, lipids (including total cholesterol, low
density lipoprotein [LDL], high density lipoprotein
[HDL] cholesterol and triglycerides) [70]. The homeo-
static model assessment (HOMA) index of insulin re-
sistance will be calculated. In addition, where consent
is given, serum samples will be stored for the analysis
of novel risk factors in the future. Participants and in-
vestigators will be blinded to the serum outcomes.
Table 2 INTENT study data collection at baseline and
months 3, 6 and 12 post-transplant in the intervention
and standard care groups
Type of data Specific measure
Demographics Age
Gender
Clinical status Acute medical issues (including acute rejection,










Deuterium dilution (total body water, fat mass)
DEXA (bone mass and fat mass)
In vivo neutron activation analysis of body nitrogen
(total body protein)







Total, LDL & HDL cholesterol and triglycerides
Insulin resistance (HOMA)
Dietary* 3-day food diary











*Only collected for intensive arm.
DEXA = Dual-energy x-ray absorptiometry; GFR = Glomerular filtration rate;
HbA1c = Haemoglobin A1c; HDL = High density lipoprotein; LDL = Low density
lipoprotein; NZPAQ-SF = New Zealand physical activity questionnaire – short
form; PG-SGA = Patient-generated subjective global assessment;
SF-36 = Short Form-36.
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post-transplant care, including full blood count, serum cre-
atinine, urea and electrolytes, other biochemistry and samples
for therapeutic drug monitoring of tacrolimus or cyclospor-
ine. The results of standard testing will not be blinded.Statistical analysis
The primary outcome (body weight at 6 months post-
transplant) will be compared between the groups using an
analysis of covariance (ANCOVA) adjusted for baseline
weight, baseline obesity (BMI ≥ 30 kg/m2), and gender.
The extent of weight gain after transplant has been shown
be significantly affected by baseline BMI [18]; gender will
be included as a covariate due to its use as a stratification
variable in the randomisation.
Secondary analyses will include analyses of change in
anthropometry (BMI, waist circumference, and waist-hip
ratio), physical function, body composition, quality of life,
and biochemistry parameters between the groups, using
ANCOVA with adjustment for relevant baseline covariates.
Repeated measures analyses using linear mixed models
with multiple covariates will be used to compare
changes in weight, anthropometry, physical function,
body composition, quality of life, and biochemistry pa-
rameters over time (baseline, 3, 6 and 12 months) between
the groups. Multiple linear regression will be used to iden-
tify significant predictors other than group allocation asso-
ciated with these changes. Variables identified as significant
will be analysed with pairwise comparisons.
Comparisons between groups for differences in variables
of interest will be conducted using Fisher’s exact test for
categorical variables, unpaired t tests for parametric vari-
ables, and Wilcoxon rank sum tests for non-parametric
variables.
All statistical analyses will be performed using appropriate
statistical software, such as STATA or SAS. The level of stat-
istical significance will be set at probability level of <0.05.
Calculation of required sample size
Using Stata statistical software to model an ANCOVA
analysis of the primary outcome at six months, with
power of 80% and alpha level of 5%, we estimate that 14
participants will be required per group, i.e. 28 in total.
To account for dropouts, we aim to recruit up to 32 par-
ticipants into the study. The effect size was estimated as
a weight difference of 5 kg at 6 months between the
groups, 74 kg (SD 9 kg) in the standard group and 69 kg
(SD 12 kg) in the intervention group. These estimates
reflect data from a non-randomised study of intensive
nutrition interventions versus standard care in a com-
parable population of kidney transplant recipients whose
weights were similar at baseline [49]. The correlation be-
tween weight at baseline and 6 months was estimated as
0.9, based on data showing a mean difference in weight
of 3.2 kg (SD 5.9 kg) between 1 and 6 months of 1299
kidney transplant recipients who received their kidney
transplant in Auckland between 1991 and 2012 (unpub-
lished observations, data on file), where the correlation
was 0.9514. Similar findings were found in an analysis
of weight change post-transplant in a comparable
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Australia (mean weight change 3.3 kg, SD 6.0 kg)
(Campbell KL, personal communication) [18].
Discussion
This trial will provide evidence on the effects of intensive
nutrition intervention on weight gain after kidney trans-
plantation. In addition, the study will also examine in de-
tail changes in other anthropometric indices (including
BMI, waist circumference and waist-hip ratio), body com-
position, physical function, and biochemistry including
glucose metabolism and markers of metabolic risk. We
hypothesise that the intervention (compared to standard
care) will result in reduced weight gain and lead to corre-
sponding reductions in BMI, waist circumference and
waist-hip ratio, improved physical function and favourable
changes in body composition including reduced fat mass
and increased muscle mass. We also hypothesise that these
changes will be associated with improvements in glucose
metabolism, reduced lipid levels and reduced insulin
resistance.
The outcomes from this research will also provide im-
portant data on the feasibility of conducting larger multi-
centre randomised trials of intensive nutrition interventions
to reduce the incidence and severity of diabetes in kidney
transplant recipients, and thus the potential to reduce the
risks of cardiovascular disease in transplant recipients.
The use of the gold-standard body composition tech-
niques including in vivo neutron activation analysis, deu-
terium dilution, total body potassium and DEXA, as well
as the indirect but more readily available measures such
as bioelectrical impedance, is a particular strength of this
study. Few investigators have the ability to perform these
gold-standard analyses and this study will provide im-
portant updated data on changes in these measures after
kidney transplantation in the current era [71]. The use
of these body composition measures will enable a much
more detailed understanding of any changes in weight and
anthropometry that are observed as a result of the inter-
vention. We will also be able to compare the surrogate
bioelectrical impedance measures that are more readily
available with gold standard measures and thus provide
important validation data in this population.
Historical data from a non-randomised study of nutrition
interventions in the early period post-transplant [49] have
been used to estimate the effect of the intervention on
weight change after transplant. More recent data are not
available to provide a more reliable estimate of the likely ef-
fect size, and it is thus possible that there may be more
variability in weight gain observed in this population,
and hence a larger sample size may be required for the
same power. Some protection, however, is afforded by
the fact that the primary outcome analysis will be ac-
complished using ANCOVA, rather than a t-test onweight change as used in the Patel study [49]. Previous
data on post-transplant weight change in our popula-
tion shows a high degree of correlation between weight
at baseline (one month) and six months, supporting the
use of an ANCOVA [72].
Due to the nature of the intervention, it is not pos-
sible to blind participants or investigators involved in
the intervention to group allocations, and thus there is
a potential risk of bias. We have attempted to minim-
ise this by using single-blind design, i.e. by having for-
mal measurements of weight and other measures that
will be reported as study outcomes performed by a
blinded investigator. In addition, to reduce the poten-
tial for confounding due to measurement variability, a
single investigator will perform all of the outcome
measurements using the same instruments throughout
the study.
Conclusions
The INTENT trial will provide important data on the
effectiveness of nutrition interventions to prevent ex-
cessive weight gain after transplantation. Given the
current lack of data from randomised controlled trials
assessing the benefit of strategies to prevent excessive
weight gain, this study therefore addresses an important
gap in current evidence regarding optimal care after
kidney transplantation.
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